Although the incidence of pediatric inflammatory bowel disease (IBD) continues to rise in Northern France, the risks of death and cancer in this population have not been characterized.
Dr Corinne Gower-Rousseau and colleagues from France evaluated all patients under 17 years, recorded in EPIMAD registry, and diagnosed between 1988 and 2004 with Crohn's disease or ulcerative colitis.
The observed incidences of death and cancer were compared with those expected in the regional general population obtained by French Statistical Institute (INSEE), and the cancer Registry from Lille.
Comparisons were performed using Fisher's exact test and were expressed using the standardized mortality ratios (SMRs) and standardized incidence ratios.
|1.3% of patients had a cancer|
|American Journal of Gastroenterology|
The research team identified a total of 698 patients, of which 360 were men, the median age at IBD diagnosis was 14 years, and the median follow-up time was 12 years.
During follow-up, the team found that the mortality rate was 0.84%, and did not differ from that in the reference population.
The researchers noted that after a median follow-up of 15 years, 1.3% of patients had a cancer, including colon, biliary tract, uterine cervix, prepuce, skin, hematological, and small bowel carcinoid.
The team observed a significantly increased risk of cancer regardless of gender and age.
The researchers found that 4 out of 9 patients who developed a cancer had received immunosuppressants or anti-tumor necrosis factor-α therapy.
Dr Gower-Rousseau's team concludes, "In this large pediatric population-based IBD cohort, mortality did not differ from that of the general population but there was a significant threefold increased risk of neoplasia."